Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14484902 | 0.73 | ALDH1A1 (0.46) | LMNAALDH1A1POLBL3MBTL1CYP1A2 | |
| SCHEMBL7013723 | 0.73 | POLB (0.58) | LMNAALDH1A1POLBL3MBTL1CYP1A2 | |
| SCHEMBL16115897 | 0.71 | NR4A2 (0.51) | LMNAGAAL3MBTL1NR4A2TSHR | |
| SCHEMBL13261931 | 0.70 | ALDH1A1 (0.54) | LMNAALDH1A1POLBL3MBTL1CYP1A2 | |
| SCHEMBL13261932 | 0.70 | LMNA (0.53) | LMNAALDH1A1POLBL3MBTL1CYP1A2 | |
| SCHEMBL879966 | 0.69 | ALDH1A1 (0.53) | LMNAALDH1A1POLBL3MBTL1CYP1A2 | |
| SCHEMBL3874161 | 0.69 | ALDH1A1 (0.53) | LMNAALDH1A1POLBL3MBTL1CYP1A2 | |
| SCHEMBL16116137 | 0.69 | NR4A2 (0.43) | LMNAGAAL3MBTL1NR4A2TSHR | |
| SCHEMBL849754 | 0.69 | ALDH1A1 (0.52) | LMNAALDH1A1GAAPOLBL3MBTL1 | |
| SCHEMBL17924282 | 0.69 | ALDH1A1 (0.59) | LMNAALDH1A1POLBL3MBTL1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169632-A1 | METHODS AND MATERIALS FOR INCREASING OR MAINTAINING NICOTINAMIDE MONONUCLEOTIDE ADENYLYL TRANSFERASE-2 (NMNAT2) POLYPEPTIDE LEVELS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169632-A1 | METHODS AND MATERIALS FOR INCREASING OR MAINTAINING NICOTINAMIDE MONONUCLEOTIDE ADENYLYL TRANSFERASE-2 (NMNAT2) POLYPEPTIDE LEVELS | NAMPT, NMT2, NNMT | LMNA 642/4885ALDH1A1 1673/4885GAA 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.